Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
iHeart comprehensive out-of-court debt restructuring
We advised an ad hoc group of noteholders and term loan lenders on the transaction
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
BrainAurora Medical Technology HK$583 million IPO
We advised BrainAurora on its IPO and HKEX listing
Veritas Technologies comprehensive debt recapitalization transaction
We advised an ad hoc group of term lenders and noteholders on the transaction
General Motors Financial $2.5 billion senior notes offering
The investment-grade notes are due 2030 and 2035
GrafTech International capital raise and exchange transaction
We advised an ad hoc group of noteholders and the first-lien term loan administrative and collateral agent on the transaction
Cintas $5.3 billion proposal to acquire UniFirst
We are advising Cintas on the proposed acquisition
Teoxane proposal to acquire Revance Therapeutics
We are advising Teoxane on the proposed acquisition
Olema Pharmaceuticals $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
J. M. Smucker cash tender offer
The offer involved five tranches of senior notes